Companies / Spyre Therapeutics, Inc. / Activity
Activity — Spyre Therapeutics, Inc.
16 moves.
Top impactInsider · CEO movesInsider · biggest buysInsider · biggest sellsInstitution · biggest movesInstitution · new positions
| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Feb 2, 2026 | Turtle Cameron CEO | Sell | Common Stock | $461.6K | -14K -2.09% | 657,540 0.75% of shares | medium |
| Jan 2, 2026 | Turtle Cameron CEO | Sell | Common Stock | $387.2K | -13K -1.85% | 674,198 0.76% of shares | medium |
| Mar 2, 2026 | Turtle Cameron CEO | Sell | Common Stock | $386.7K | -9K -1.40% | 642,540 0.73% of shares | medium |
| Mar 2, 2026 | Turtle Cameron CEO | Sell | Common Stock | $246.2K | -6K -0.90% | 651,640 0.74% of shares | medium |
| Mar 3, 2026 | Burrows Scott L Executive | Sell | Common Stock | $93.3K | -2K -2.29% | 98,194 0.11% of shares | low |
| Jan 2, 2026 | Turtle Cameron CEO | Sell | Common Stock | $69.7K | -2K -0.33% | 672,007 0.76% of shares | low |
| Mar 3, 2026 | Burrows Scott L Executive | Exercise | Common Stock | $36.3K | +3K +2.55% | 100,494 0.11% of shares | low |
| Feb 2, 2026 | Turtle Cameron CEO | Sell | Common Stock | $30.5K | -957 -0.14% | 671,583 0.76% of shares | low |
| Mar 3, 2026 | Burrows Scott L Executive | Sell | Common Stock | $8.3K | -200 -0.20% | 97,994 0.11% of shares | low |
| Jan 2, 2026 | Turtle Cameron CEO | Sell | Common Stock | $3.2K | -100 -0.01% | 671,907 0.76% of shares | low |
| Jan 21, 2026 | Henderson Michael Thomas Director | Other | Common Stock | $0 | +63K +60.00% | 168,606 0.19% of shares | low |
| Jan 9, 2026 | King-Jones Heidy Executive | Grant | Stock Option (Right to Buy) | — | +140K | 140,000 0.16% of shares | low |
| Jan 9, 2026 | Turtle Cameron CEO | Grant | Stock Option (Right to Buy) | — | +528K | 528,000 0.60% of shares | low |
| Mar 3, 2026 | Burrows Scott L Executive | Exercise | Stock Option (Right to Buy) | — | -3K -0.62% | 402,357 0.46% of shares | low |
| Jan 9, 2026 | Burrows Scott L Executive | Grant | Stock Option (Right to Buy) | — | +140K | 140,000 0.16% of shares | low |
| Jan 9, 2026 | Sloan Sheldon Executive | Grant | Stock Option (Right to Buy) | — | +140K | 140,000 0.16% of shares | low |